Substance P(1-7) affects the expression of dopamine D2 receptor mRNA in male rat brain during morphine withdrawal

Peptides

Volumn 24, Issue 1, 2003, Pages 147-153

  Zhou, Qin ^a   Frändberg, Per Anders ^a   Kindlundh, Anna M S ^a   Le Grevès, Pierre ^a   Nyberg, Fred ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

D2 receptor mRNA; Dopamine; Frontal cortex; Morphine withdrawal; Nucleus accumbens; SP1 7; Substance P

Indexed keywords

DOPAMINE 2 RECEPTOR; HEPTAPEPTIDE; MESSENGER RNA; MORPHINE; NALOXONE; OPIATE; SODIUM CHLORIDE; SUBSTANCE P;

ANIMAL TISSUE; ARTICLE; CANNULA; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG WITHDRAWAL; FRONTAL CORTEX; IMPLANTATION; LATERAL BRAIN VENTRICLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; REDUCTION; WITHDRAWAL REFLEX;

ANIMALIA;

EID: 0037255632     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00287-5     Document Type: Article

References (57)

1. Bassareo V., Tanda G., Di Chiara G. Increase of extracellular dopamine in the medial prefrontal cortex during spontaneous and naloxone-precipitated opiate abstinence. Psychopharmacology. 122(2):1995;202-205.
2. Blasig J., Herz A., Reinhold K., Zieglgansberger S. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia. 33:1973;19-38.
3. Blasig J., Herz A. Precipitated morphine withdrawal in rats as a tool in opiate research. Curr. Dev. Psychopharmacol. 4:1977;129-149.
4. Bristow L.J., Hogg J.E., Hutson P.H. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology. 36:1997;241-250.
5. Bunzow J.R., Van Tol H.H., Grandy D.K., Albert P., Salon J., Christie M.et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 336:1988;783-787.
6. Cappendijk S.L., de Vries R., Dzoljic M.R. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharm. 3:1993;111-116.
7. Chahl L.A., Johnston P.A. Effect of the nonpeptide NK-1 receptor antagonist CP-96,245 on the morphine withdrawal response of guinea-pigs. Regul. Pept. 46:1993;373-375.
8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
9. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J.H.et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature. 392:1998;394-397.
10. Elliott P.J., Alpert J.E., Bannon M.J., Iversen S.D. Selective activation of mesolimbic and mesocortical dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral tegmental area. Brain Res. 363:1986;145-147.
11. Giros B., Sokoloff P., Martres M.P., Riou J.F., Emorine L.J., Schwartz J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 342:1989;923-929.
12. Hall M.E., Stewart J.M. The substance P fragment SP(1-7) stimulates motor behavior and nigral dopamine release. Pharmacol. Biochem. Behav. 41(1):1992;75-78.
13. Harris G.C., Aston-Jones G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature. 371:1994;155-157.
14. Hoffman U., Plesan A., Wiesenfeld-Hallin Z. Genetic difference in morphine sensitivity, tolerance and withdrawal in rats. Brain. Res. 806:1998;232-237.
15. Igwe O.J., Kim D.C., Larson A.A. Specific binding of substance P aminoterminal heptapeptide (SP(1-7)) to mouse brain and spinal cord membranes. J. Neurosci. 10:1990;3653-3663.
16. Jackson D.M., Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol. Ther. 64:1994;291-369.
17. Jung M., Michaud J.C., Steinberg R., Barnouin M.C., Hayar A., Mons G.et al. Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin NK3 receptor stimulation. Neuroscience. 74(2):1996;403-414.
18. Koob G.F., Sanna P.P., Bloom F.E. Neuroscience of addiction. Neuron. 21:1998;467-476.
19. Koob G.F., Wall T.L., Bloom F.E. Nucleus accumbens as a substrate for the aversive stimulus effects of opiate withdrawal. Psychopharmacology. 98:1989;530-534.
20. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J.et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645.
21. Kreeger J.S., Larson A.A. Substance P (1-7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice. Eur. J. Pharmacol. 238:1993;111-115.
22. Kreeger J.S., Larson A.A. The substance P amino-terminal metabolite substance P (1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice. J. Pharmacol. Exp. Ther. 279:1996;662-667.
23. 3H ]DAMGO binding by substance P (SP) and SP fragments in the mouse brain and spinal cord via mu1 interactions Neuropeptides. 13:1989;225-233.
24. Le Grevès P., Huang W., Johansson P., Thornwall M., Zhou Q., Nyberg F. Effects of anabolic-androgenic steroid on the regulation of the NMDA receptor NR1, NR2A and NR2B subunit mRNAs in brain regions of the male rat. Neurosci. Lett. 226(1):1997;61-64.
25. Liu Z., Lyrenas S., Thornwall M., Le Grevès P., Nyberg F. Elevated cerebrospinal fluid level of substance P and decreased undecapeptidase activity at term pregnancy. Neuropeptides. 31(5):1997;415-421.
26. Lu X.Y., Ghasemzadeh M.B., Kalivas P.W. Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the neucleus accumbens. Neuroscience. 82:1998;767-780.
27. Maggi C.A., Lecci A., Garret C., Giuliani S. Spinal effects of selective NK-1 and NK-2 receptor antagonists on bladder motility in anesthetized rats. Regul. Pept. 46:1993;389-391.
28. Maggio J.E. Tachykinins. Annu. Rev. Neurosci. 11:1988;13-28.
29. Maldonado R., Girdlestone D., Roques B.P. RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci. Lett. 156:1993;135-140.
30. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78(1):1998;189-225.
31. Murtra P., Sheasby A.M., Hunt S.P., De Felipe C. Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature. 405:2000;180-183.
32. Nyberg F, Terenius, L. Enzymatic inactivation of neuropeptides. In: Henriksen JH, editor. Degradation of bioactive substances: physiology and patho-physiology. New York: CRC Press Inc.; 1991. p. 189-200.
33. Nyberg F, Vaeroy H, Terenius L. Opioid peptides and substance P in cerebrospinal fluid: regulation and significance to pain. In: Olessen J, Edvinson L, editors. Basic mechanism of headache. Amsterdam: Elsevier; 1988a. p. 311-25.
34. Olmedo R., Hoffman R.S. Withdrawal syndromes. Emerg. Med. Clin. North Am. 18:2000;273-288.
35. Persson S., Le Grevès P., Thörnwall M., Eriksson U., Silberring J., Nyberg F. Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Progr. Brain Res. 104:1995;111-130.
36. Reid M.S., Herrera M.M., Terenius L., Ungerstedt U. Intranigral substance P modulation of striatal dopamine: interaction with N-terminal and C-terminal substance P fragments. Brain Res. 526(2):1990;228-234.
37. Ribeiro da Silva A., Hökfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides. 34(5):2000;256-271.
38. Robbins T.W. Chemical neuromodulation of frontal-executive functions in humans and other animals. Exp. Brain Res. 133:2000;130-138.
39. Schmidt-Mutter C., Muller C., Zwiller J., Gobaille S., Maitre M. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. Neuropsychopharmacol. 21:2000;662-669.
40. Sharpe L.G., Jaffe J.H. Captopril and capsaicin modify opioid withdrawal in the morphine-dependent rat. Pharmacol. Biochem. Behav. 33(4):1989;899-902.
41. Skilling S.R., Smullin D.H., Larson A.A. Differential effects of C- and N-terminal substance P metabolites on the release of amino acid neurotransmitters from spinal cord: potential role in nociception. J. Neurosci. 10(4):1990;1309-1318.
42. Svensson P., Hurd Y. Specific reductions of striatal prodynorphin and D1 dopamine receptor messenger RNAs during cocaine abstinence. Mol. Brain Res. 56:1998;162-168.
43. Staubli U., Huston J.P. Central action of substance P: possible role in reward. Behav. Neural. Biol. 43:1985;100-108.
44. Stewart J.M., Hall M.E., Harkins J., Frederickson R.C.A., Terenius L., Hökfelt T.et al. A fragment of substance P with specific central activity: SP(1-7). Peptides. 3:1982;851-857.
45. Stinus L., Le Moal M., Koob G.F. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience. 37:1990;767-773.
46. Tamiya R., Hanada M., Kawai Y., Inagaki S., Takagi H. Substance P afferents have synaptic contacts with dopaminergic neurons in the ventral tegmental area of rat. Neurosci. Lett. 110:1990;11-15.
47. Tomaz C., Silva A.C., Nogueira P.J. Long-lasting memotropic effect of substance P and its N-terminal fragment (SP1-7) on avoidance learning. Braz. J. Med. Biol. Res. 30(2):1997;231-233.
48. Trujillo K.A. Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology. 13:1995;301-307.
49. Trujillo K.A., Akil H. Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug Alcohol Depend. 38:1995;139-154.
50. Watling K.J., Krause J.E. The rising sun shines on substance P and related peptides. Trends. Pharmacol. Sci. 14:1993;81-84.
51. Wei E., Sigel S.S., Loh H.H., Way E.L. Central sites of naloxone-precipitated shaking in the anesthetized, morphine-dependent rat. J. Pharmacol. Exp. Ther. 195:1975;480-487.
52. Woldbye D.P., Klemp K., Madsen T.M. Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors. J. Pharmacol. Exp. Ther. 284:1998;633-636.
53. Yukhananov R.Y., Larson A.A. An N-terminal fragment of substance P, substance P(1-7), down-regulates neurokinin-l binding in the mouse spinal cord. Neurosci. Lett. 178:1994;163-166.
54. Zhou Q., Liu Z., Ray A., Huang W., Karlsson K., Nyberg F. Alteration in the brain content of substance P (1-7) during withdrawal in morphine-dependent rats. Neuropharmacology. 37:1998;1545-1552.
55. Zhou Q., Le Grevès P., Ragnar F., Nyberg F. Intracerebroventricular injection of the N-terminal substance P fragment SP1-7 regulates the expression of the N-methyl-D-aspartate receptor NR1, NR2A and NR2B subunit mRNAs in the rat brain. Neurosci. Lett. 291:2000;109-112.
56. Zhou Q., Karlsson K., Liu Z., Johansson P., Le Grevès M., Kiuru A.et al. Substance P endopeptidase-like activity is altered in various regions of the rat central nervous system during morphine tolerance and withdrawal. Neuropharmacology. 41:2001;246-253.
57. Zhou Q., Nyberg F. Injection of substance P (SP) N-terminal fragment SP1-7 into the ventral tegmental area modulates the levels of nucleus accumbens dopamine and dihydroxyphenylacetic acid in male rats during morphine withdrawal. Neurosci. Lett. 320:2002;117-120.